Abeona therapeutics reports third quarter 2023 financial results and corporate developments

Abeona's first-ever u.s. biologics license application (bla) submission completed in september 2023 fda decision on priority review and acceptance of bla for pz-cel (prademagene zamikeracel, formerly known as eb-101) in recessive dystrophic epidermolysis bullosa (rdeb) expected by late-november 2023 initiated commercial readiness activities for potential u.s. launch of pz-cel cleveland, nov. 13, 2023 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo) today reported financial results for the third quarter of 2023 and provided corporate updates. “in the third quarter, we made substantial progress in our evolution from a late-stage clinical development company to one with significant commercial opportunity,” said vish seshadri, chief executive officer of abeona.
ABEO Ratings Summary
ABEO Quant Ranking